iRhythm Holdings, Inc. Common Stock
IRTC
$117.92
-5.92%
iRhythm Holdings is a digital healthcare company that designs and commercializes ambulatory cardiac monitoring solutions, primarily its Zio System—a wearable biosensor and cloud-based analytics platform for detecting arrhythmias. As a pioneer in long-term continuous cardiac monitoring, iRhythm holds a strong competitive position in the medical device industry, leveraging FDA-cleared technology and a growing installed base. The current investor narrative centers on the company's accelerating revenue growth, recent profitability milestone in Q4 2025, and expanding commercial adoption, though questions remain about its path to sustained profitability and competitive pressures from emerging patch-based monitors.…
IRTC
iRhythm Holdings, Inc. Common Stock
$117.92
Investment Opinion: Should I buy IRTC Today?
Rating: Buy. iRhythm is a high-growth turnaround story with accelerating revenue, improving profitability, and a valuation near historical lows, supported by unanimous analyst Buy ratings and an average EPS estimate of $6.34 for next fiscal year.
Supporting Evidence: Revenue growth accelerated to 27.1% YoY in Q4 2025, far exceeding the industry average of ~5-10%. Gross margin improved to 70.9% from 68.8% in Q1 2025, and free cash flow turned positive at $14.5M in Q4. The PS ratio of 7.6x is near the bottom of its 5-year historical range of 15x-55x, implying significant upside potential if profitability materializes. The forward PE of 120.3x reflects high growth expectations, but the PEG ratio of 2.07 suggests the premium is partially justified by growth.
Risks & Conditions: The biggest risks are failure to sustain profitability, revenue deceleration, and competitive pressure. This Buy would downgrade to Hold if revenue growth falls below 15% or if the company reports a quarterly loss. It would upgrade to Strong Buy if the PS ratio compresses below 5x or if the company achieves positive TTM net income. Overall, iRhythm appears undervalued relative to its historical multiples and growth trajectory, but fairly valued to slightly overvalued on a forward earnings basis given the high PE.
Sign up to view all
IRTC 12-Month Price Forecast
iRhythm's accelerating revenue growth and recent profitability milestone provide a strong foundation for a bullish outlook. The stock's valuation near historical lows offers a favorable risk/reward, especially if the company can sustain its earnings momentum. However, the high debt load and negative TTM margins warrant caution, and the stock's recent downtrend indicates lingering market skepticism. The base case of moderate growth and gradual multiple expansion is most likely, but the bull case has significant upside if the company delivers on analyst expectations. We would upgrade to high confidence if the company reports two consecutive quarters of positive net income and revenue growth above 20%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on iRhythm Holdings, Inc. Common Stock's 12-month outlook, with a consensus price target around $153.29 and implied upside of +30.0% versus the current price.
Average Target
$153.29
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$94 - $153
Analyst target range
iRhythm is covered by 4 analysts, with a consensus Buy rating (all 4 rate it Buy or equivalent). The average analyst target price is not explicitly provided, but based on the estimated EPS of $6.34 for the next fiscal year and a forward PE of 120.3x, the implied target is approximately $763 (6.34 * 120.3), representing over 500% upside from the current price of $126.48. However, this seems unrealistic and likely reflects a data error or misinterpretation. Given the limited analyst data, we note that the consensus is bullish, with recent upgrades from Evercore ISI (Outperform from In Line) and maintained Buy ratings from Citigroup, Truist, and Needham. The high target of $6.42 EPS implies strong growth expectations, while the low target of $6.26 suggests a narrow range, indicating high conviction among analysts. The wide spread between current price and implied targets suggests either a significant undervaluation or that the forward estimates are overly optimistic. Investors should monitor upcoming earnings for confirmation of the profitability trajectory.
Bulls vs Bears: IRTC Investment Factors
iRhythm presents a compelling turnaround story with accelerating revenue growth (27.1% YoY in Q4 2025), a recent GAAP profitability milestone, and improving margins and cash flow. The stock trades at a PS ratio of 7.6x, near the bottom of its historical range, and analysts are unanimously bullish with a Buy rating. However, the company still has negative TTM net margins and a high debt-to-equity ratio of 4.79, while the stock has been in a sustained downtrend, underperforming the market by over 30% in the past year. The single most important tension is whether the company can sustain its profitability trajectory and deliver on the high forward EPS estimates of $6.34, which would justify the current valuation and potentially drive significant upside. Currently, the bull case has stronger evidence given the accelerating growth and improving fundamentals, but the bear case highlights the risk of execution failure and continued market skepticism.
Bullish
- Accelerating Revenue Growth: Q4 2025 revenue grew 27.1% YoY to $208.9M, up from 11.4% growth in Q4 2024, with sequential acceleration from $158.7M in Q1 2025. This robust demand for the Zio System indicates strong market share gains in ambulatory cardiac monitoring.
- Achieved GAAP Profitability Milestone: iRhythm posted net income of $5.6M (EPS $0.17) in Q4 2025, a dramatic turnaround from a net loss of -$30.7M in Q1 2025. This demonstrates the company's ability to scale and achieve operating leverage.
- Improving Gross Margin and Cash Flow: Gross margin improved to 70.9% in Q4 2025 from 68.8% in Q1 2025, and free cash flow turned positive at $14.5M in Q4, with TTM FCF of $34.5M. This reduces dependence on external financing and supports intrinsic value.
- Strong Analyst Consensus and Upgrades: All 4 analysts rate the stock a Buy, with recent upgrades from Evercore ISI (Outperform from In Line). The average EPS estimate of $6.34 for next fiscal year implies significant earnings growth, reflecting high conviction in the profitability trajectory.
Bearish
- High Debt-to-Equity Ratio: The debt-to-equity ratio of 4.79 is elevated, indicating significant leverage. While the current ratio of 4.63 provides liquidity, the high debt burden could constrain financial flexibility and increase vulnerability to rising interest rates.
- Negative TTM Net Margin and ROE: Despite Q4 profitability, the trailing twelve-month net margin remains negative at -5.96%, and ROE is deeply negative at -29.2%. This indicates the company is not yet sustainably profitable on a full-year basis, and profitability may be volatile.
- Premium Valuation vs. Industry Peers: The PS ratio of 7.6x represents a 69% premium to the Medical-Devices industry average of ~4.5x. While justified by higher growth, any growth deceleration could lead to multiple compression and significant downside.
- Stock in Sustained Downtrend: The stock is down 11.4% over the past year, significantly underperforming the S&P 500's +19.1% gain. It sits at 59.7% of its 52-week range, closer to the low of $100.85 than the high of $212.00, reflecting persistent selling pressure.
IRTC Technical Analysis
iRhythm's stock is in a sustained downtrend over the past year, with a 1-year price change of -11.4%, significantly underperforming the S&P 500's +19.1% gain. The current price of $126.48 sits at 59.7% of its 52-week range (low $100.85, high $212.00), indicating the stock is closer to its lows than highs—suggesting a potential value opportunity but also reflecting persistent selling pressure. The stock has been range-bound between $100 and $130 since March 2026, failing to reclaim its 2025 highs. Short-term momentum has improved notably, with a 1-month price change of +19.9% and a 3-month change of +8.3%, diverging from the negative 1-year trend. This recent rally could signal a potential trend reversal or mean reversion, especially given the stock's relative strength versus the S&P 500 over 1 month (+21.1%), though the 3-month relative strength remains negative at -5.3%. The 52-week low of $100.85 provides key support, while the 52-week high of $212.00 represents major resistance. A breakout above $130 (recent range top) could signal a shift to recovery, while a breakdown below $100.85 would likely accelerate selling. With a beta of 1.273, iRhythm is 27.3% more volatile than the market, amplifying both upside and downside risks for position sizing.
Beta
1.27
1.27x market volatility
Max Drawdown
-46.2%
Largest decline past year
52-Week Range
$101-$212
Price range past year
Annual Return
-11.3%
Cumulative gain past year
| Period | IRTC Return | S&P 500 |
|---|---|---|
| 1m | +3.6% | +2.0% |
| 3m | +2.3% | +10.6% |
| 6m | -34.3% | +8.3% |
| 1y | -11.3% | +20.4% |
| ytd | -32.7% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IRTC Fundamental Analysis
Revenue growth is accelerating strongly: Q4 2025 revenue of $208.9 million grew 27.1% year-over-year, up from 11.4% growth in Q4 2024. The trailing twelve-month revenue reached $747.1 million, driven by commercial payors ($111.7M in Q4) and healthcare institutions ($34.3M). The multi-quarter trend shows sequential acceleration from Q1 2025's $158.7M to Q4's $208.9M, indicating robust demand for the Zio System. This growth trajectory supports the investment case for a company gaining market share in cardiac monitoring. iRhythm achieved GAAP profitability in Q4 2025 with net income of $5.6 million (EPS $0.17), a dramatic turnaround from a net loss of -$30.7 million in Q1 2025. Gross margin improved to 70.9% in Q4 2025, up from 68.8% in Q1 2025, reflecting operating leverage. However, the trailing twelve-month net margin remains negative at -5.96%, and operating margin was -4.9%, indicating the company is still not sustainably profitable on a full-year basis. The balance sheet shows a debt-to-equity ratio of 4.79, which is high, but the current ratio of 4.63 indicates strong liquidity. Free cash flow turned positive at $14.5 million in Q4 2025, and trailing twelve-month FCF reached $34.5 million, a significant improvement from negative FCF in prior quarters. ROE is deeply negative at -29.2% due to accumulated losses, but the improving cash flow generation reduces dependence on external financing.
Quarterly Revenue
$208890000.0B
2025-12
Revenue YoY Growth
+27.12%
YoY Comparison
Gross Margin
70.88%
Latest Quarter
Free Cash Flow
$34521000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IRTC Overvalued?
Since net income is positive on a trailing basis (TTM net income of -$34.4M, but Q4 positive), we lead with the PE ratio. The trailing PE is -127.7x (negative due to TTM losses), while the forward PE is 120.3x, implying the market expects significant earnings growth. The gap between negative trailing and positive forward PE reflects the market's pricing of a profitability inflection. The PS ratio of 7.6x provides a cleaner comparison given the recent profitability transition. Compared to the Medical-Devices industry average PS ratio of approximately 4.5x (estimated), iRhythm trades at a 69% premium. This premium is justified by its 27% revenue growth rate, which far exceeds the industry average of ~5-10%, and its dominant position in ambulatory cardiac monitoring. Historically, iRhythm's PS ratio has ranged from 15x to 55x over the past five years. The current 7.6x is near the bottom of its historical range, suggesting the stock is cheap relative to its own history. This low multiple reflects the market's skepticism about sustained profitability, but if the company delivers on earnings expectations, multiple expansion could drive significant upside.
PE
-127.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -530x~256x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-1557.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: iRhythm's high debt-to-equity ratio of 4.79 indicates significant leverage, which could strain cash flows if interest rates remain elevated. While the current ratio of 4.63 provides ample liquidity, the company's TTM net margin of -5.96% and negative ROE of -29.2% highlight that profitability is not yet sustainable on a full-year basis. The recent Q4 2025 net income of $5.6M is a positive step, but any reversal in operating leverage could quickly erode earnings. Revenue concentration in the Zio System also poses a risk if competitive alternatives gain traction.
Market & Competitive Risks: The stock's PS ratio of 7.6x trades at a 69% premium to the industry average, making it vulnerable to valuation compression if growth decelerates. With a beta of 1.273, the stock is highly correlated to market movements, and the 1-year relative strength of -30.5% versus the S&P 500 indicates persistent underperformance. Competitive threats from emerging patch-based monitors could pressure market share, and the high short ratio of 5.57 days suggests significant bearish sentiment that could amplify any negative news.
Worst-Case Scenario: If iRhythm fails to sustain profitability, revenue growth decelerates below 10%, or competitive pressures intensify, the stock could retest its 52-week low of $100.85. From the current price of $126.48, this represents a potential downside of -20.3%. In a more severe scenario, if the company faces a liquidity crisis or regulatory setback, the stock could decline further, potentially approaching the historical max drawdown of -46.2%, implying a price near $68.00. Investors should be prepared for a loss of up to 20-46% in adverse conditions.
FAQ
The primary risks are: 1) Financial risk from a high debt-to-equity ratio of 4.79 and negative TTM net margins, which could lead to cash flow strain. 2) Competitive risk from emerging patch-based monitors that could erode market share. 3) Valuation risk from a PS ratio that is a 69% premium to the industry, making the stock vulnerable to multiple compression if growth slows. 4) Market risk from a beta of 1.273, meaning the stock is 27% more volatile than the market, and a short ratio of 5.57 days, indicating elevated bearish sentiment. The most severe risk is a failure to sustain profitability, which could drive the stock back to its 52-week low of $100.85.
Our 12-month outlook incorporates three scenarios. The base case (45% probability) sees the stock trading in a range of $130-$160, driven by 15-20% revenue growth and modest profitability. The bull case (30% probability) targets $180-$212, with sustained 20%+ growth and multiple expansion. The bear case (25% probability) sees the stock falling to $100-$115 if growth decelerates or profitability falters. The most likely scenario is the base case, assuming the company can maintain its growth trajectory and deliver on profitability expectations. Key catalysts include the next earnings report and any major contract wins.
IRTC's PS ratio of 7.6x is a 69% premium to the medical devices industry average of ~4.5x, suggesting it is overvalued relative to peers. However, this premium is justified by its 27.1% revenue growth, which far exceeds the industry average. More importantly, the PS ratio is near the bottom of its 5-year historical range of 15x-55x, indicating the stock is undervalued relative to its own history. The forward PE of 120.3x is high, but the PEG ratio of 2.07 suggests the growth premium is reasonable. Overall, the stock appears undervalued on a historical basis but fairly valued to slightly overvalued on a forward earnings basis.
IRTC presents a compelling risk/reward for growth investors. The stock trades at a PS ratio of 7.6x, near its 5-year low, while revenue is accelerating at 27.1% YoY. Analysts are unanimously bullish with a Buy rating and an average EPS estimate of $6.34 for next fiscal year. However, the company has a high debt-to-equity ratio of 4.79 and negative TTM net margins of -5.96%, so it is not for the faint-hearted. It is a good buy for those who believe the profitability turnaround is sustainable and can tolerate potential downside to the 52-week low of $100.85 (-20% from current levels).
IRTC is better suited for long-term investment given its growth stage and volatility. The stock has a beta of 1.273 and has been in a downtrend over the past year, making it risky for short-term trading. The company is in a turnaround phase with improving fundamentals, and the valuation near historical lows suggests potential for multi-year appreciation if the profitability story plays out. Short-term traders may find opportunities around earnings events, but the high short interest and volatility can lead to sharp moves. A minimum holding period of 12-18 months is recommended to allow the turnaround to materialize and for the market to re-rate the stock.